

## Pharnext to attend Jefferies 2016 London Healthcare Conference

**Paris, November 3<sup>rd</sup> 2016 – Pharnext SA (FR00111911287 - ALPHA)**, a French biopharmaceuticals company developing an advanced portfolio of products in the field of neurodegenerative diseases, announces today its participation at the Jefferies 2016 London Healthcare Conference taking place November 16-17 at the Waldorf Hotel in London, UK.

This Conference is the largest healthcare meeting in Europe dedicated to companies from around the world: biotechnologies, pharmaceuticals, generics, medtechs and healthcare services. Last year, the Jefferies conference hosted over 300 participating companies, 1,200 attendees and 3,700 B2B and investor meetings.

### CONTACTS :

#### Pharnext

Pierre Schwich  
Directeur Financier

[investors@pharnext.com](mailto:investors@pharnext.com)

+33 (0)1 41 09 22 30

#### NewCap

Relations Investisseurs  
Julie Coulot

[pharnext@newcap.eu](mailto:pharnext@newcap.eu)

+33 (0)1 44 71 20 40

#### Media Relations (Europe)

Alize RP  
Caroline Carmagnol  
Margaux Pronost

[pharnext@alizerp.com](mailto:pharnext@alizerp.com)

+33 (0)1 44 54 36 64

#### Media Relations (US)

Russo Partners  
Tony Russo, Ph.D.  
Matt Middleman, M.D.

[matt.middleman@russopartnersllc.com](mailto:matt.middleman@russopartnersllc.com)

+1 212-845-4272

### ABOUT PHARNEXT

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPIE®. Pharnext identifies and develops synergetic combinations of drugs that are already being used for other diseases. These PLEOMEDICAMENT® are developed at new lower doses and repositioned into new indications. The PLEOMEDICAMENT® offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, visit [www.pharnext.com](http://www.pharnext.com).